Oishi Peter, Grobe Albert, Benavidez Eileen, Ovadia Boaz, Harmon Cynthia, Ross Gregory A, Hendricks-Munoz Karen, Xu Jie, Black Stephen M, Fineman Jeffrey R
Department of Pediatrics, UC San Francisco, 505 Parnassus Ave., Box 0106, San Francisco, CA 94143-0106, USA.
Am J Physiol Lung Cell Mol Physiol. 2006 Feb;290(2):L359-66. doi: 10.1152/ajplung.00019.2005. Epub 2005 Oct 28.
Previous in vivo studies indicate that inhaled nitric oxide (NO) decreases nitric oxide synthase (NOS) activity and that this decrease is associated with significant increases in pulmonary vascular resistance (PVR) upon the acute withdrawal of inhaled NO (rebound pulmonary hypertension). In vitro studies suggest that superoxide and peroxynitrite production during inhaled NO therapy may mediate these effects, but in vivo data are lacking. The objective of this study was to determine the role of superoxide in the decrease in NOS activity and rebound pulmonary hypertension associated with inhaled NO therapy in vivo. In control lambs, 24 h of inhaled NO (40 ppm) decreased NOS activity by 40% (P<0.05) and increased endothelin-1 levels by 64% (P<0.05). Withdrawal of NO resulted in an acute increase in PVR (60.7%, P<0.05). Associated with these changes, superoxide and peroxynitrite levels increased more than twofold (P<0.05) following 24 h of inhaled NO therapy. However, in lambs treated with polyethylene glycol-conjugated superoxide dismutase (PEG-SOD) during inhaled NO therapy, there was no change in NOS activity, no increase in superoxide or peroxynitrite levels, and no increase in PVR upon the withdrawal of inhaled NO. In addition, endothelial NOS nitration was 18-fold higher (P<0.05) in control lambs than in PEG-SOD-treated lambs following 24 h of inhaled NO. These data suggest that superoxide and peroxynitrite participate in the decrease in NOS activity and rebound pulmonary hypertension associated with inhaled NO therapy. Reactive oxygen species scavenging may be a useful therapeutic strategy to ameliorate alterations in endogenous NO signaling during inhaled NO therapy.
以往的体内研究表明,吸入一氧化氮(NO)会降低一氧化氮合酶(NOS)的活性,且这种降低与吸入NO急性撤药后肺血管阻力(PVR)显著增加(反弹性肺动脉高压)有关。体外研究提示,吸入NO治疗期间超氧化物和过氧亚硝酸盐的产生可能介导了这些效应,但缺乏体内数据。本研究的目的是确定超氧化物在与吸入NO治疗相关的NOS活性降低和反弹性肺动脉高压中的作用。在对照羔羊中,吸入24小时NO(40 ppm)使NOS活性降低40%(P<0.05),内皮素-1水平升高64%(P<0.05)。撤去NO导致PVR急性升高(60.7%,P<0.05)。与这些变化相关的是,吸入NO治疗24小时后,超氧化物和过氧亚硝酸盐水平增加了两倍多(P<0.05)。然而,在吸入NO治疗期间用聚乙二醇共轭超氧化物歧化酶(PEG-SOD)治疗的羔羊中,NOS活性没有变化,超氧化物或过氧亚硝酸盐水平没有升高,撤去吸入NO后PVR也没有升高。此外,吸入NO 24小时后,对照羔羊的内皮型NOS硝化程度比PEG-SOD治疗的羔羊高18倍(P<0.05)。这些数据表明,超氧化物和过氧亚硝酸盐参与了与吸入NO治疗相关的NOS活性降低和反弹性肺动脉高压。清除活性氧可能是一种有用的治疗策略,以改善吸入NO治疗期间内源性NO信号的改变。